H.C. Wainwright analyst Sara Nik initiated coverage of Pasithea Therapeutics with a Buy rating and $3 price target. The firm says the company has a next-generation MEK inhibitor "set to tackle both orphan and oncology markets." The analyst views Pasithea's pipeline as being the "best-in-class comprehensive attack" on the MAPK pathways, potentially yielding access to a $20B potential market in multiple indications.
